Trials / Completed
CompletedNCT04328077
LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 101 (actual)
- Sponsor
- Terns, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of TERN-101 in non-cirrhotic NASH patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TERN-101 | Investigational drug |
| OTHER | Placebo | Matching placebo |
Timeline
- Start date
- 2020-06-18
- Primary completion
- 2021-05-19
- Completion
- 2021-05-19
- First posted
- 2020-03-31
- Last updated
- 2022-08-09
- Results posted
- 2022-06-14
Locations
31 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04328077. Inclusion in this directory is not an endorsement.